Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 41, 2011 - Issue 4
125
Views
0
CrossRef citations to date
0
Altmetric
Animal Pharmacokinetics and Metabolism

Metabolism of [2-14C]p-hydroxyphenyl acetic acid in rat, monkey and human hepatocytes and in bile-duct cannulated rats

, &
Pages 312-319 | Received 11 Oct 2010, Accepted 12 Nov 2010, Published online: 14 Dec 2010
 

Abstract

  1. We determined the metabolism of [2-14C]p-hydroxyphenyl acetic acid (p-HPA) in rat (male, Sprague–Dawley), monkey (male, Cynomolgus), and human (male, Caucasian) hepatocytes, and in bile-duct cannulated (BDC) rats (male, Sprague–Dawley). Unchanged p-HPA ranged from 87.0 to 92.6% of the total radioactivity (TRA) in the extracts of rat, monkey, and human hepatocytes. Metabolites M1 (a glucuronide conjugate of p-HPA) and M2 (a glycine conjugate of p-HPA) were detected, accounting for 1–4% of TRA.

  2. After an oral dose of [2-14C]p-HPA to BDC rats, p-HPA-related components was predominantly excreted in urine, accounting for 83% of the dose. Bile excretion was limited, accounting for only 1.5% of the dose. Unchanged p-HPA was the predominant radioactivity in plasma (84.6% of the TRA in 1-h pooled plasma) and urine (69.6% of the dose). Metabolites M1, M2, and M3 (a glucuronide of p-HPA) were all detected in plasma, urine, and bile as minor components.

  3. In summary, p-HPA was not metabolized extensively in rat, monkey, and human hepatocytes. In rats, absorption and elimination of p-HPA were nearly complete with urinary excretion of the unchanged p-HPA as the predominant route of elimination after oral dosing. No oxidative metabolites were detected, suggesting a minimal role for P450 enzymes in its overall metabolic clearance. Therefore, p-HPA has a low potential for drug–drug interactions mediated by the concomitant inhibitors and inducers of P450 enzymes.

Acknowledgements

We thank Dr. Hongjian Zhang (PharmaResources, Shanghai, China) for helpful discussions.

Declaration of interest

All of the studies reported herein were supported by Bristol-Myers Squibb Co. All of the authors are employees of Bristol-Myers Squibb Co.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.